





BSW Formulary Update – November 2022

New additions to BSWformulary

[Beclometasone dipropionate 172mcg/formoterol fumarate 5mcg/glycopyrronium 9mcg](#) per dose pMDI (**Trimbow 172/5/9®**) and

[Indacaterol acetate 114mcg/glycopyrronium bromide 46mcg/mometasone furoate 136mcg](#) per dose DPI (**Enerzair®** Breezhaler)

These are triple inhalers with high dose steroid component. Added to BSWformulary as an option for adult patients with **asthma** requiring high dose ICS/LABA/LAMA in one formulation. Both inhalers have been assigned **GREEN TLS** to reflect that primary care have experience of titrating ICS upwards and adding in LAMA for asthma patients. However, we recommend at this stage in therapy primary care should '*consider referring for advice*' to help flag patients that may benefit from advice from, or referral to, secondary care. These inhalers will be included in the BSW asthma guidance which is currently being produced in conjunction with local specialist respiratory teams. Enerzair Breezhaler DPI has a low carbon footprint  but Trimbow pMDI has a high carbon footprint . **Note the importance of correct product selection.** These high strength triple inhalers are included **only for use in asthma** and are not currently licensed for COPD. Trimbow pMDI remains available in a lower strength (87/5/9) which is used in asthma and COPD.

- [Estradiol 1mg/micronised progesterone 100mg](#) oral capsules (**Bijuve®**) added with **GREEN TLS** This is a bioidentical preparation and a useful second line option if adverse effects experienced with synthetic preparations. Note the [BSW HRT formulary guidance](#) is currently being updated.
- [Cefiderocol 1g](#) powder for solution for infusion (**Fectroja®**) and [ceftazidime-avibactam 2g/0.5g](#) injection (**Zavicefta®**) Added with **RED TLS**, microbiology approval and only in line with NICE.
- [Nadolol 80mg](#) tablets (Corgard®) added with **AMBER TLS** for use in long QT syndrome and catecholamine polymorphic ventricular tachycardia in line with the European Society of Cardiology guidelines.

Prescribing Guidance

- UPDATED - [BSW Oral Nutrition Supplements Formulary](#) – Aymes Actagain Juice replaces Altrajuce as second line juice style ONS. **AMBER TLS**. Should only be prescribed on the recommendation of a dietitian or specialist nurse with a review plan in place.
- NEW – [Use of SGLT2 inhibitors in T2DM, Heart Failure and Kidney Disease](#).
- UPDATED (Urgent Chairs action) - [BSW Management of Infections in Primary Care Full Guideline](#) and [BSW Quick Ref Guide children](#) have been updated to incorporate [NHSE/UKHSA interim guidance on Group A Streptococcus for children](#).



Other BSWformulary website updates

- [Lidocaine 10% spray](#) **RED TLS**. Aligned for use across all Trusts.
- [Icosapent ethyl 998mg oral capsules](#) **AMBER TLS** Note added (as per BNF) that Icosapent is **Not suitable** for people with known hypersensitivity to fish and/or shellfish, people with hypersensitivity to soya or peanuts or vegans/vegetarians.
- Info on the 'Yellow Book' has been included at the top of [Chapter 02.08.02 \(oral anticoagulants\)](#): *The anticoagulant book (often referred to as the yellow book or OAT book) has been updated [Oct 2022]. The book is intended for people on warfarin or other vitamin K antagonist anticoagulants. A new information book on Direct Oral Anticoagulant (DOAC) is also available intended for people on apixaban, edoxaban, rivaroxaban and dabigatran; known collectively as direct oral anticoagulants. Supplies of the existing booklets will continue until they have run out and then the new booklets will start to appear. They are available via [NHS Forms](#) or [Primary Care Support England \(PCSE\)](#) They are available for download here: [Anticoagulant/OAT book](#) [DOAC book](#)*

Working with paediatric teams across RUH, GWH and SFT, we are continuing to build up the paediatric chapter of BSWformulary and have recently reviewed some entries for [cardiovascular drugs \(paediatrics\)](#) and [oral hydrocortisone \(paediatrics\)](#). Please note this chapter remains 'under construction' and is not a comprehensive list of medicines used in children. Use bswicb.formulary@nhs.net for queries about drugs or Traffic Light Status for use in children.

What the BSW ICB formulary team are currently working on

- Reviewing the national NHSE [Shared Care Protocols](#) for implementation locally. The BSW APC has prioritised adoption of these according to existing local protocols (and their date of review) and patient safety factors. Amiodarone and valproate SCAs are identified as BSW priorities.
- Working with colleagues in community provider services and urology to build a comprehensive continence products formulary.

The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems and Optimise Profiles are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email bswicb.formulary@nhs.net